Investing.com -- Bank of America has reinstated coverage of Bausch + Lomb Corp (NYSE:BLCO) with an "underperform" rating and a price target of $18, amid reduced prospects of a private equity buyout.
The rating of the stock follows a report that Blackstone (NYSE:BX) pulled out of a consortium considering a takeover of the eye care company. Bausch&Lomb’s shares, which had risen 33% since mid-September on buyout speculation, fell 12% after the news.
“A takeout is not imminent and we would expect it to rekindle investor concerns on the timing/likelihood of the spin. BLCO’s fundamentals have been solid over the last several quarters but we think the stock will be a relative underperformer without more clarity on the spin,” analyst wrote.
The uncertainty around a potential spin-off from its parent company, Bausch Health, remains a significant overhang. The parent company still owns 88% of Bausch&Lomb and has provided limited details on separation plans since the company’s IPO in May 2022.
BofA noted that while Bausch&Lomb has shown solid growth in sales and margins, investor focus is likely to remain on the spin-off’s timing and feasibility. Without clarity on separation, the stock is expected to underperform relative to the market.
Related Articles
Greece to buy artillery systems from Israel and drones from US, officials say
Column-Bleak times for copper smelters as conversion fees slump: Andy Home
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。